search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Flexibility and Optimized


The Cove a™ V


Hemodynamics


The Covera™ Vascular Cove ed Stent is a flexible, self-expanding endoprosthesis uniquely designed to conform to native vessels in hallenging A


ular Covered Stent is a flexible, self-expanding


endoprosthesis uniquely designed to conform to native vessels in challenging AV anatomy.


The unique, contoured edges are engineered to provide wall apposition and promote laminar flow, while the option of either a straight or flar


unique, contoured edges are engineered to pr vide w ition and promote laminar flo


ght or flared configuration provides optimized flow at the venous anastomosis. A flared stent graft design can help minimize the degree of disturbed flow and avoid excessive oversizing when the outflow vein is greater than the inflow vein.


ation pr vides optimized flow at


us anastomosis. A flared stent graft design can help he degree of disturbed flow and avoid ex hen the outflow vein is gr


er than the inflow vein. while the option of either


46 %


of AVeNew patients received a flared configuration


Optional flared end


The AVeNEW Clinical Study was a prospective, multi-center, randomized, concurrently-controlled clinical study of the Covera™ Vascular Covered Stent in the treatment of stenosis in the venous outflow of the AV fistula access circuits. 280 patients were treated with the Covera Vascular Covered Stent at 24 investigational sites in the US, Europe, Australia and New Zealand. Patients were distributed globally with at least 50-75% being treated in the US. Target Lesion Primary Patency (TLPP) of 78.7% vs. 47.9% with PTA alone was defined as the interval following the index intervention until the next clinically-driven reintervention at or adjacent to the original treatment site or until the extremity was abandoned for permanent access. AVeNEW Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe AZ


bd.com BD, Tempe, AZ, USA, 1 800 321 4254 Please consult product labels and package inserts for indications, contraindications, hazards, warnings, cautions, and information for use.


BD, the BD Logo, and Covera are trademarks of Becton, Dickinson and Company or its affiliates. © 2021 BD. All rights reserved. Illustrations by Mike Austin. Copyright © 2021. All rights reserved. BD-16102


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40